Literature DB >> 11186047

Funding issues for Victorian hospitals: the risk-adjusted vision beyond casemix funding.

K Antioch1, M Walsh.   

Abstract

This paper discusses casemix funding issues in Victoria impacting on teaching hospitals. For casemix payments to be acceptable, the average price and cost weights must be set at an appropriate standard. The average price is based on a normative, policy basis rather than benchmarking. The 'averaging principle' inherent in cost weights has resulted in some AN-DRG weights being too low for teaching hospitals that are key State-wide providers of high complexity services such as neurosurgery and trauma. Casemix data have been analysed using international risk adjustment methodologies to successfully negotiate with the Victorian State Government for specified grants for several high complexity AN-DRGs. A risk-adjusted capitation funding model has also been developed for cystic fibrosis patients treated by The Alfred, called an Australian Health Maintenance Organisation (AHMO). This will facilitate the development of similar models by both the Victorian and Federal governments.

Entities:  

Mesh:

Year:  2000        PMID: 11186047     DOI: 10.1071/ah000145

Source DB:  PubMed          Journal:  Aust Health Rev        ISSN: 0156-5788            Impact factor:   1.990


  3 in total

1.  The risk-adjusted vision beyond casemix (DRG) funding in Australia. International lessons in high complexity and capitation.

Authors:  Kathryn M Antioch; Michael K Walsh
Journal:  Eur J Health Econ       Date:  2004-06

2.  Risk adjustment policy options for casemix funding: international lessons in financing reform.

Authors:  Kathryn M Antioch; Randall P Ellis; Steve Gillett; Daniel Borovnicar; Ric P Marshall
Journal:  Eur J Health Econ       Date:  2007-02-02

3.  [DRG reimbursement for multiple trauma patients -- a comparison with the comprehensive hospital costs using the German trauma registry].

Authors:  M Grotz; T Schwermann; R Lefering; S Ruchholtz; J M Graf v d Schulenburg; C Krettek; H C Pape
Journal:  Unfallchirurg       Date:  2004-01       Impact factor: 1.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.